Mental disorder

Summary

Mental disorder (MONDO:0005084) is a disease (an umbrella term covering 14 Mondo subtypes) with 40 cohort genes (223 GWAS associations across 91 studies) and 493 clinical trials. Top therapeutic interventions include brexpiprazole, fluoxetine, and paroxetine.

At a glance

• Umbrella term: 14 Mondo subtypes
• Cohort genes: 40
• GWAS associations: 223
• ClinVar variants: 3
• Clinical trials: 493

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mental disorder
Mondo ID	MONDO:0005084
EFO	EFO:0000677
SNOMED CT	74732009
UMLS	C0004936
MedGen	14047
Is cancer (heuristic)	no

Also known as: disorder of mental process · mental or behavioral disorder · mental or behavioural disorder · mental process disease

Data availability: 3 ClinVar variants · 223 GWAS associations (91 studies).

Disease family

An umbrella term covering 14 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder

Related subtypes (13): sexual disorder, dissociative disorder, impulse control disorder, personality disorder, cognitive disorder, factitious disorder, substance-related disorder, somatoform disorder, eating disorder, enuresis, Alice in Wonderland syndrome, catatonia, body integrity dysphoria

Subtypes (14): akinetopsia, cortical deafness, pain agnosia, tactile agnosia, visual agnosia, psychosexual disorder, drug-induced mental disorder, alcohol-induced mental disorder, adjustment disorder, mood disorder, psychotic disorder, developmental disorder of mental health, anxiety disorder, disruptive behavior disorder

Genetics & variants

GWAS landscape

223 GWAS associations across 91 studies. Top hits map to 17 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs429358	2e-56	APOE	T	0.23
chr9:133616083	2e-18		A	0.1
rs530915272	3e-16	MCM3AP, MCM3AP-AS1	G	4.38
chr20:32434638	7e-15		AG	0.99
chr7:114559888	2e-13		A	0.06
rs528608991	4e-13	LINC02379 - H3P15	C	2.79
rs555304890	8e-13	DUSP23 - FCRL6	T	2.25
rs551486755	9e-13	BSNDP4 - RNU6-417P	C	3.99
rs528204842	1e-12	RP1L1	G	3.36
rs545467829	3e-12	CPD	A	3.55
rs183791137	6e-12	AKR1C3 - AKR1C5P	C	3.91
rs141847690	7e-12	CDH4	G	2.02
rs563884503	7e-12	LINC02488 - TMEM161B	G	3.84
rs12580615	9e-12	ANKS1B	G	3.21
rs188277002	1e-11	SHE	T	2.78
chr11:28602326	1e-11		T	0.05
rs529494389	2e-11	ABCC4	G	3.81
rs368327902	2e-11	CLIC5	G	2.9
rs185458001	2e-11	OR7K1P - LINC02306	C	3.02
chr2:44927279	2e-11		C	0.05
rs555187562	3e-11	NDUFV3	C	3.75
rs184664617	3e-11	MIR5696 - CREG2	G	2.67
rs148179018	3e-11	CBR4-DT - SH3RF1	G	3.18
chr15:78631503	3e-11		G	0.05
rs537425976	4e-11	LINC02006	A	2.59
rs143634281	4e-11	LINC01717 - LINC01774	A	4.23
rs565838897	4e-11	MAPK10	A	2.46
chr2:417167	1e-10		C	0.1
rs7118422	3e-10	STIM1	T	1.17
chr2:44954195	9e-10		C	0.05

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90042861	Jiang L	2021	156,442	296,621	A generalized linear mixed model association tool for biobank-scale data.
GCST90042802	Jiang L	2021	57,861	89,409	A generalized linear mixed model association tool for biobank-scale data.
GCST90102280	Meng P	2022	56,863	319,943	Associations between genetic loci, environment factors and mental disorders: a genome-wide survival analysis using the UK Biobank data.
GCST90042862	Jiang L	2021	52,417	401,764	A generalized linear mixed model association tool for biobank-scale data.
GCST90473248	UK Biobank Whole-Genome Sequencing Consortium	2025	50,715	407,725	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90042804	Jiang L	2021	48,729	97,076	A generalized linear mixed model association tool for biobank-scale data.
GCST007777	Schork AJ	2019	46,008	19,526	A genome-wide association study of shared risk across psychiatric disorders implicates gene regulation during fetal neurodevelopment.
GCST011006	Liu X	2020	43,902	19,790	Genetic factors underlying the bidirectional relationship between autoimmune and mental disorders - findings from a Danish population-based study.
GCST011007	Liu X	2020	42,866	19,790	Genetic factors underlying the bidirectional relationship between autoimmune and mental disorders - findings from a Danish population-based study.
GCST90473255	UK Biobank Whole-Genome Sequencing Consortium	2025	41,745	416,695	Whole-genome sequencing of 490,640 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	2
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	48

MAF distribution

Bucket	Variants
common (>=0.05)	5
low_freq (0.01-0.05)	0
rare (<0.01)	20
unknown	25

Functional consequences

Consequence	Count
unknown	23
intron_variant	16
intergenic_variant	9
missense_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr19:44908684								Tier 4: intronic/intergenic
rs429358	19	44908684	T>C	0.14	missense_variant	APOE	2e-56	Tier 1: coding
chr9:133616083							2e-18	Tier 4: intronic/intergenic
rs530915272	21	46259184	G>A	0	intron_variant	MCM3AP, MCM3AP-AS1	3e-16	Tier 4: intronic/intergenic
chr20:32434638							7e-15	Tier 4: intronic/intergenic
chr7:114559888							2e-13	Tier 4: intronic/intergenic
rs528608991	4	126106138	C>T	0.001	intergenic_variant	LINC02379 - H3P15	4e-13	Tier 4: intronic/intergenic
rs555304890	1	159782750	T>C	0.001	intergenic_variant	DUSP23 - FCRL6	8e-13	Tier 4: intronic/intergenic
rs551486755	7	62803110	C>G,T	0	intergenic_variant	BSNDP4 - RNU6-417P	9e-13	Tier 4: intronic/intergenic
rs528204842	8	10625943	G>A,T	0.001	intron_variant	RP1L1	1e-12	Tier 4: intronic/intergenic
rs545467829	17	30388536	A>G	0.001	intron_variant	CPD	3e-12	Tier 4: intronic/intergenic
rs183791137	10	5107966	C>G,T	0.001	intergenic_variant	AKR1C3 - AKR1C5P	6e-12	Tier 4: intronic/intergenic
rs141847690	20	61659755	G>C,T	0.002	intron_variant	CDH4	7e-12	Tier 4: intronic/intergenic
rs563884503	5	87920587	G>A,T	0.001	intron_variant	LINC02488 - TMEM161B	7e-12	Tier 4: intronic/intergenic
rs12580615	12	99359379	G>A,C	0	intron_variant	ANKS1B	9e-12	Tier 4: intronic/intergenic
rs188277002	1	154499864	T>C	0.001	intron_variant	SHE	1e-11	Tier 4: intronic/intergenic
chr11:28602326							1e-11	Tier 4: intronic/intergenic
rs529494389	13	95293261	G>A	0	intron_variant	ABCC4	2e-11	Tier 4: intronic/intergenic
rs368327902	6	46069142	G>T	0.001	intergenic_variant	CLIC5	2e-11	Tier 4: intronic/intergenic
rs185458001	14	25439545	C>T	0	intergenic_variant	OR7K1P - LINC02306	2e-11	Tier 4: intronic/intergenic
chr2:44927279							2e-11	Tier 4: intronic/intergenic
rs555187562	21	42908262	C>T	0	intron_variant	NDUFV3	3e-11	Tier 4: intronic/intergenic
rs184664617	2	101330038	G>A,T	0.001	intron_variant	MIR5696 - CREG2	3e-11	Tier 4: intronic/intergenic
rs148179018	4	169076107	G>A	0.001	intergenic_variant	CBR4-DT - SH3RF1	3e-11	Tier 4: intronic/intergenic
chr15:78631503							3e-11	Tier 4: intronic/intergenic
rs537425976	3	153931143	A>G	0	intron_variant	LINC02006	4e-11	Tier 4: intronic/intergenic
rs143634281	1	208906269	A>G	0	intergenic_variant	LINC01717 - LINC01774	4e-11	Tier 4: intronic/intergenic
rs565838897	4	86323209	A>G,T	0	intron_variant	MAPK10	4e-11	Tier 4: intronic/intergenic
chr2:417167							1e-10	Tier 4: intronic/intergenic
rs7118422	11	3912065	T>C	0.49	intron_variant	STIM1	3e-10	Tier 4: intronic/intergenic

ClinVar germline variants

3 retrieved; paginated sample, class counts are floors:

2 uncertain significance, 1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
3062000	NM_001379291.1(BRD4):c.703C>T (p.Gln235Ter)	BRD4	Likely pathogenic	criteria provided, single submitter
217510	NC_000002.10:g.[51151955_51190352del;51440969_51481281del]		Uncertain significance	no assertion criteria provided
2671883	NM_001379291.1(BRD4):c.883A>C (p.Thr295Pro)	BRD4	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 19 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
STIM1	Orphanet:2593	Tubular aggregate myopathy
STIM1	Orphanet:317430	Combined immunodeficiency due to STIM1 deficiency
STIM1	Orphanet:3204	Stormorken-Sjaastad-Langslet syndrome
TRPS1	Orphanet:502	Trichorhinophalangeal syndrome type 2
TRPS1	Orphanet:77258	Trichorhinophalangeal syndrome type 1
BRD4	Orphanet:199	Cornelia de Lange syndrome
BRD4	Orphanet:443167	NUT midline carcinoma
CNTNAP2	Orphanet:163681	CNTNAP2-related developmental and epileptic encephalopathy
MYO18B	Orphanet:447974	Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome
RIN2	Orphanet:217335	RIN2 syndrome
NALCN	Orphanet:1146	Distal arthrogryposis type 1
NALCN	Orphanet:1147	Sheldon-Hall syndrome
NALCN	Orphanet:2053	Freeman-Sheldon syndrome
NALCN	Orphanet:562528	Congenital limbs-face contractures-hypotonia-developmental delay syndrome
NALCN	Orphanet:700336	Hypotonia-speech impairment-severe cognitive delay syndrome due to NALCN deficiency
IFT88	Orphanet:791	Retinitis pigmentosa
PHF8	Orphanet:85287	X-linked intellectual disability, Siderius type
POMGNT2	Orphanet:899	Walker-Warburg syndrome
PTPRF	Orphanet:180188	Isolated congenital breast hypoplasia/aplasia

Cohort genes → proteins

40 cohort genes, 39 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	39
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
STIM1	HGNC:11386	ENSG00000167323	Q13586	Stromal interaction molecule 1	gwas
TRPS1	HGNC:12340	ENSG00000104447	Q9UHF7	Zinc finger transcription factor Trps1	gwas
BRD4	HGNC:13575	ENSG00000141867	O60885	Bromodomain-containing protein 4	clinvar
CNTNAP2	HGNC:13830	ENSG00000174469	Q9UHC6	Contactin-associated protein-like 2	gwas
CACNG5	HGNC:1409	ENSG00000075429	Q9UF02	Voltage-dependent calcium channel gamma-5 subunit	gwas
SORBS1	HGNC:14565	ENSG00000095637	Q9BX66	Sorbin and SH3 domain-containing protein 1	gwas
SHC4	HGNC:16743	ENSG00000185634	Q6S5L8	SHC-transforming protein 4	gwas
SEMA6D	HGNC:16770	ENSG00000137872	Q8NFY4	Semaphorin-6D	gwas
ASTN2	HGNC:17021	ENSG00000148219	O75129	Astrotactin-2	gwas
MYO18B	HGNC:18150	ENSG00000133454	Q8IUG5	Unconventional myosin-XVIIIb	gwas
RIN2	HGNC:18750	ENSG00000132669	Q8WYP3	Ras and Rab interactor 2	gwas
NALCN	HGNC:19082	ENSG00000102452	Q8IZF0	Sodium leak channel NALCN	gwas
NPAS3	HGNC:19311	ENSG00000151322	Q8IXF0	Neuronal PAS domain-containing protein 3	gwas
RUFY1	HGNC:19760	ENSG00000176783	Q96T51	RUN and FYVE domain-containing protein 1	gwas
CCNL1	HGNC:20569	ENSG00000163660	Q9UK58	Cyclin-L1	gwas
IFT88	HGNC:20606	ENSG00000032742	Q13099	Intraflagellar transport protein 88 homolog	gwas
PDLIM1	HGNC:2067	ENSG00000107438	O00151	PDZ and LIM domain protein 1	gwas
PHF8	HGNC:20672	ENSG00000172943	Q9UPP1	Histone lysine demethylase PHF8	gwas
DAOA	HGNC:21191	ENSG00000182346	P59103	D-amino acid oxidase regulator	gwas
CNTN5	HGNC:2175	ENSG00000149972	O94779	Contactin-5	gwas
CYCSP44	HGNC:24418	ENSG00000233548		CYCS pseudogene 44	gwas
ADM	HGNC:259	ENSG00000148926	P35318	Pro-adrenomedullin	gwas
POMGNT2	HGNC:25902	ENSG00000144647	Q8NAT1	Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2	gwas
LRRIQ3	HGNC:28318	ENSG00000162620	A6PVS8	Leucine-rich repeat and IQ domain-containing protein 3	gwas
FAM110B	HGNC:28587	ENSG00000169122	Q8TC76	Protein FAM110B	gwas
DLGAP1	HGNC:2905	ENSG00000170579	O14490	Disks large-associated protein 1	gwas
NCKAP5	HGNC:29847	ENSG00000176771	O14513	Nck-associated protein 5	gwas
ERC2	HGNC:31922	ENSG00000187672	O15083	ERC protein 2	gwas
DIPK1A	HGNC:32213	ENSG00000154511	Q5T7M9	Divergent protein kinase domain 1A	gwas
LEKR1	HGNC:33765	ENSG00000197980	Q6ZMV7	Protein LEKR1	gwas
TMEM212	HGNC:34295	ENSG00000186329	A6NML5	Transmembrane protein 212	gwas
GABRR1	HGNC:4090	ENSG00000146276	P24046	Gamma-aminobutyric acid receptor subunit rho-1	gwas
ANXA1	HGNC:533	ENSG00000135046	P04083	Annexin A1	gwas
IGSF5	HGNC:5952	ENSG00000183067	Q9NSI5	Immunoglobulin superfamily member 5	gwas
MAD1L1	HGNC:6762	ENSG00000002822	Q9Y6D9	Mitotic spindle assembly checkpoint protein MAD1	gwas
B3GALT5	HGNC:920	ENSG00000183778	Q9Y2C3	Beta-1,3-galactosyltransferase 5	gwas
PRKCE	HGNC:9401	ENSG00000171132	Q02156	Protein kinase C epsilon type	gwas
PTPRF	HGNC:9670	ENSG00000142949	P10586	Receptor-type tyrosine-protein phosphatase F	gwas
PTPRN2	HGNC:9677	ENSG00000155093	Q92932	Receptor-type tyrosine-protein phosphatase N2	gwas
PTPRU	HGNC:9683	ENSG00000060656	Q92729	Receptor-type tyrosine-protein phosphatase U	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
STIM1	Stromal interaction molecule 1	Acts as a Ca(2+) sensor that gates two major inward rectifying Ca(2+) channels at the plasma membrane: Ca(2+) release-activated Ca(2+) (CRAC) channels and arachidonate-regulated Ca(2+)-selective (ARC) channels.
TRPS1	Zinc finger transcription factor Trps1	Transcriptional repressor.
BRD4	Bromodomain-containing protein 4	Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation.
CNTNAP2	Contactin-associated protein-like 2	Required for gap junction formation.
CACNG5	Voltage-dependent calcium channel gamma-5 subunit	Regulates the gating properties of AMPA-selective glutamate receptors (AMPARs).
SORBS1	Sorbin and SH3 domain-containing protein 1	Plays a role in tyrosine phosphorylation of CBL by linking CBL to the insulin receptor.
SHC4	SHC-transforming protein 4	Activates both Ras-dependent and Ras-independent migratory pathways in melanomas.
SEMA6D	Semaphorin-6D	Shows growth cone collapsing activity on dorsal root ganglion (DRG) neurons in vitro.
ASTN2	Astrotactin-2	Mediates recycling of the neuronal cell adhesion molecule ASTN1 to the anterior pole of the cell membrane in migrating neurons.
MYO18B	Unconventional myosin-XVIIIb	May be involved in intracellular trafficking of the muscle cell when in the cytoplasm, whereas entering the nucleus, may be involved in the regulation of muscle specific genes.
RIN2	Ras and Rab interactor 2	Ras effector protein.
NALCN	Sodium leak channel NALCN	Voltage-gated ion channel responsible for the resting Na(+) permeability that controls neuronal excitability.
NPAS3	Neuronal PAS domain-containing protein 3	May play a broad role in neurogenesis.
RUFY1	RUN and FYVE domain-containing protein 1	Activating adapter involved in cargo sorting from early/recycling endosomes.
CCNL1	Cyclin-L1	Regulatory component of the cyclin-L-CDK11 complex that regulates transcription and pre-mRNA splicing.
IFT88	Intraflagellar transport protein 88 homolog	Positively regulates primary cilium biogenesis.
PDLIM1	PDZ and LIM domain protein 1	Cytoskeletal protein that may act as an adapter that brings other proteins (like kinases) to the cytoskeleton.
PHF8	Histone lysine demethylase PHF8	Histone lysine demethylase with selectivity for mono- and dimethylated residues.
DAOA	D-amino acid oxidase regulator	May suppress DAO (D-amino acid oxidase) and SOD1 activity and promote their degradation.
CNTN5	Contactin-5	Contactins mediate cell surface interactions during nervous system development.
ADM	Pro-adrenomedullin	Adrenomedullin/ADM and proadrenomedullin N-20 terminal peptide/PAMP are peptide hormones that act as potent hypotensive and vasodilatator agents.
POMGNT2	Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2	O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein.
FAM110B	Protein FAM110B	May be involved in tumor progression.
DLGAP1	Disks large-associated protein 1	Part of the postsynaptic scaffold in neuronal cells.
ERC2	ERC protein 2	Thought to be involved in the organization of the cytomatrix at the nerve terminals active zone (CAZ) which regulates neurotransmitter release.
GABRR1	Gamma-aminobutyric acid receptor subunit rho-1	Rho subunit of the pentameric ligand-gated chloride channels responsible for mediating the effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain.
ANXA1	Annexin A1	Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process.
IGSF5	Immunoglobulin superfamily member 5	Provides, together with MAGI1, an adhesion machinery at tight junctions, which may regulate the permeability of kidney glomerulus and small intestinal epithelial cells.
MAD1L1	Mitotic spindle assembly checkpoint protein MAD1	Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate.
B3GALT5	Beta-1,3-galactosyltransferase 5	Catalyzes the transfer of Gal to GlcNAc-based acceptors with a preference for the core3 O-linked glycan GlcNAc(beta1,3)GalNAc structure.
PRKCE	Protein kinase C epsilon type	Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motil…
PTPRF	Receptor-type tyrosine-protein phosphatase F	Possible cell adhesion receptor.
PTPRN2	Receptor-type tyrosine-protein phosphatase N2	Plays a role in vesicle-mediated secretory processes.
PTPRU	Receptor-type tyrosine-protein phosphatase U	Tyrosine-protein phosphatase which dephosphorylates CTNNB1.

Protein-family classification

Druggable: 10 · Difficult: 9 · Unknown: 21 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Phosphatase	3	6.3×	0.096
Complement	1	6.7×	0.398
Antibody/Immunoglobulin	3	2.2×	0.398
Scaffold/PPI	4	1.7×	0.398
Ion channel	1	2.8×	0.484
Kinase	2	1.4×	0.568
Transcription factor	5	1.0×	0.619
Other/Unknown	21	0.9×	0.721

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
STIM1	Other/Unknown	no		SAM, SAM/pointed_sf, SOAR_STIM1/2
TRPS1	Transcription factor	no		Znf_GATA, Znf_C2H2_type, Znf_NHR/GATA
BRD4	Other/Unknown	no		Bromodomain, Bromodomain_CS, NET_dom
CNTNAP2	Other/Unknown	no		FA58C, EGF, Laminin_G
CACNG5	Other/Unknown	no		PMP22/EMP/MP20/Claudin, VDCC_gsu, VDCC_g5su
SORBS1	Scaffold/PPI	no		SH3_domain, SoHo_dom, SORBS1_SH3
SHC4	Scaffold/PPI	no		SH2, PID_Shc-like, PTB/PI_dom
SEMA6D	Scaffold/PPI	no		Semap_dom, Plexin_repeat, WD40/YVTN_repeat-like_dom_sf
ASTN2	Complement	yes		MACPF, Astrotactin, FN3_sf
MYO18B	Other/Unknown	no		Myosin_head_motor_dom-like, P-loop_NTPase, MYSc_Myo18
RIN2	Scaffold/PPI	no		RA_dom, SH2, VPS9
NALCN	Ion channel	yes		Ion_trans_dom, Volt_channel_dom_sf, NALCN
NPAS3	Transcription factor	no		PAS, bHLH_dom, PAS_fold_3
RUFY1	Transcription factor	no		Znf_FYVE, Znf_RING, Run_dom
CCNL1	Other/Unknown	no		Cyclin_C-dom, Cyclin_N, Cyclin-like_dom
IFT88	Other/Unknown	no		Sel1-like, TPR-like_helical_dom_sf, TPR_rpt
PDLIM1	Transcription factor	no		PDZ, Znf_LIM, Zasp-like_motif
PHF8	Transcription factor	no	1.14.11.65	Znf_PHD, JmjC_dom, Znf_FYVE_PHD
DAOA	Other/Unknown	no		DAOA
CNTN5	Antibody/Immunoglobulin	yes		Ig_sub2, Ig_sub, FN3_dom
CYCSP44	Other/Unknown	no
ADM	Other/Unknown	no		Pro-ADM, Calcitonin/adrenomedullin, Adrenomedullin-reg_peptide
POMGNT2	Antibody/Immunoglobulin	yes	2.4.1.312	FN3_dom, Glycosyltransferase_61, Ig-like_fold
LRRIQ3	Other/Unknown	no		Leu-rich_rpt, LRR_dom_sf, LRR-IQ_domain_protein
FAM110B	Other/Unknown	no		FAM110_N, FAM110, FAM110_C
DLGAP1	Other/Unknown	no		SAPAP
NCKAP5	Other/Unknown	no		Nckap5l, NCKAP5_C
ERC2	Other/Unknown	no		ELKS/CAST
DIPK1A	Kinase	yes		FAM69_kinase_dom, FAM69_N
LEKR1	Other/Unknown	no		LEKR1
TMEM212	Other/Unknown	no
GABRR1	Other/Unknown	no		GABAA/Glycine_rcpt, Neurotrans-gated_channel_TM, Neur_channel
ANXA1	Other/Unknown	no		Annexin, ANX1, Annexin_repeat_CS
IGSF5	Antibody/Immunoglobulin	yes		Ig_sub, Ig-like_dom, Ig_I-set
MAD1L1	Other/Unknown	no		Mad1
B3GALT5	Other/Unknown	no		Glyco_trans_31
PRKCE	Kinase	yes	2.7.11.13	C2_dom, Prot_kinase_dom, AGC-kinase_C
PTPRF	Phosphatase	yes	3.1.3.48	PTP_cat, Tyr_Pase_dom, Tyr_Pase_cat
PTPRN2	Phosphatase	yes	3.1.3.48	PTP_cat, Tyr_Pase_dom, Tyr_Pase_cat
PTPRU	Phosphatase	yes	3.1.3.48	PTP_cat, Tyr_Pase_dom, MAM_dom

Expression context

Cohort genes with no expression data: 0.

36 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	1
moderate (6-20)	1
broad (>20)	38
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	7
middle temporal gyrus	5
male germ line stem cell (sensu Vertebrata) in testis	5
sural nerve	4
corpus callosum	4
primordial germ cell in gonad	4
Brodmann (1909) area 23	4
endothelial cell	4
bronchial epithelial cell	3
left testis	3
right testis	3
lateral nuclear group of thalamus	3
gastrocnemius	2
hindlimb stylopod muscle	2
calcaneal tendon	2
tendon of biceps brachii	2
left ventricle myocardium	2
dorsal root ganglion	2
trigeminal ganglion	2
jejunal mucosa	2

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
STIM1	237	ubiquitous	marker	gastrocnemius, muscle of leg, hindlimb stylopod muscle
TRPS1	284	ubiquitous	marker	mammary duct, epithelium of mammary gland, calcaneal tendon
BRD4	300	ubiquitous	marker	buccal mucosa cell, sural nerve, tendon of biceps brachii
CNTNAP2	127	broad	marker	corpus callosum, superior frontal gyrus, C1 segment of cervical spinal cord
CACNG5	46	tissue_specific	yes	primordial germ cell in gonad, anterior cingulate cortex, Brodmann (1909) area 9
SORBS1	287	ubiquitous	marker	blood vessel layer, saphenous vein, left ventricle myocardium
SHC4	191	broad	yes	buccal mucosa cell, trigeminal ganglion, dorsal root ganglion
SEMA6D	251	broad	marker	jejunal mucosa, substantia nigra pars reticulata, substantia nigra pars compacta
ASTN2	236	ubiquitous	marker	buccal mucosa cell, trigeminal ganglion, dorsal root ganglion
MYO18B	148	broad	marker	apex of heart, gastrocnemius, hindlimb stylopod muscle
RIN2	296	ubiquitous	marker	choroid plexus epithelium, tendon of biceps brachii, hair follicle
NALCN	201	ubiquitous	marker	middle temporal gyrus, Brodmann (1909) area 23, corpus callosum
NPAS3	215	broad	marker	endothelial cell, ventricular zone, corpus callosum
RUFY1	134	ubiquitous	marker	monocyte, leukocyte, calcaneal tendon
CCNL1	293	ubiquitous	marker	mucosa of stomach, granulocyte, left uterine tube
IFT88	284	ubiquitous	marker	bronchial epithelial cell, sperm, epithelium of bronchus
PDLIM1	283	ubiquitous	marker	lower lobe of lung, nasal cavity epithelium, mucosa of urinary bladder
PHF8	251	ubiquitous	marker	right testis, sural nerve, left testis
DAOA	1		marker	endothelial cell, upper leg skin, lower lobe of lung
CNTN5	130	broad	marker	adrenal tissue, primordial germ cell in gonad, islet of Langerhans
CYCSP44	11		yes	male germ line stem cell (sensu Vertebrata) in testis, buccal mucosa cell, triceps brachii
ADM	288	ubiquitous	marker	vena cava, type B pancreatic cell, pericardium
POMGNT2	245	ubiquitous	marker	lateral nuclear group of thalamus, right hemisphere of cerebellum, cardiac muscle of right atrium
LRRIQ3	165	broad	yes	male germ line stem cell (sensu Vertebrata) in testis, left testis, right testis
FAM110B	238	ubiquitous	marker	cortical plate, cartilage tissue, middle temporal gyrus
DLGAP1	214	broad	marker	Brodmann (1909) area 23, endothelial cell, primary visual cortex
NCKAP5	132	broad	marker	corpus callosum, cerebellar vermis, ventricular zone
ERC2	195	broad	marker	middle temporal gyrus, Brodmann (1909) area 23, orbitofrontal cortex
DIPK1A	275	ubiquitous	marker	endothelial cell, Brodmann (1909) area 23, middle temporal gyrus
LEKR1	165	ubiquitous	marker	buccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis, right uterine tube

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRD4	7,883
ANXA1	4,269
IFT88	3,166
STIM1	3,074
MAD1L1	2,947
TRPS1	2,588
PHF8	2,579
PTPRF	2,473
PRKCE	2,158
CNTNAP2	2,097

Intra-cohort edges

A	B	Sources
CCNL1	LEKR1	string_interaction
CNTN5	CNTNAP2	string_interaction
PTPRN2	STIM1	biogrid_interaction

Structural data

PDB: 21 · AlphaFold-only: 18 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRD4	O60885	619
GABRR1	P24046	26
PTPRF	P10586	13
SORBS1	Q9BX66	11
ADM	P35318	8
B3GALT5	Q9Y2C3	8
STIM1	Q13586	6
PHF8	Q9UPP1	6
NALCN	Q8IZF0	5
ANXA1	P04083	5
MAD1L1	Q9Y6D9	5
ASTN2	O75129	3
POMGNT2	Q8NAT1	3
DLGAP1	O14490	3
PTPRN2	Q92932	3
RUFY1	Q96T51	2
PDLIM1	O00151	2
CNTN5	O94779	2
PRKCE	Q02156	2
PTPRU	Q92729	2
CNTNAP2	Q9UHC6	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
LEKR1	Q6ZMV7	92.75
DIPK1A	Q5T7M9	83.20
IFT88	Q13099	77.20
TMEM212	A6NML5	74.31
ERC2	O15083	74.26
CACNG5	Q9UF02	72.86
LRRIQ3	A6PVS8	70.18
CCNL1	Q9UK58	68.90
SEMA6D	Q8NFY4	67.95
IGSF5	Q9NSI5	66.04
RIN2	Q8WYP3	64.30
MYO18B	Q8IUG5	60.66
FAM110B	Q8TC76	59.48
SHC4	Q6S5L8	59.12
NPAS3	Q8IXF0	56.50
TRPS1	Q9UHF7	49.12
DAOA	P59103	46.78
NCKAP5	O14513	43.93

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 99. Enrichment computed across 40 evidence-associated genes (21 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 21 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Smooth Muscle Contraction	2	25.3×	0.138	SORBS1, ANXA1
Muscle contraction	3	11.0×	0.138	STIM1, SORBS1, ANXA1
DAG1 core M3 glycosylations	1	90.6×	0.219	POMGNT2
Formyl peptide receptors bind formyl peptides and many other ligands	1	68.0×	0.219	ANXA1
Blood group systems biosynthesis	1	54.4×	0.219	B3GALT5
Calcitonin-like ligand receptors	1	49.4×	0.219	ADM
Elevation of cytosolic Ca2+ levels	1	34.0×	0.219	STIM1
Platelet calcium homeostasis	1	34.0×	0.219	STIM1
Lewis blood group biosynthesis	1	32.0×	0.219	B3GALT5
Other semaphorin interactions	1	28.6×	0.219	SEMA6D
Receptor-type tyrosine-protein phosphatases	1	27.2×	0.219	PTPRF
Synaptic adhesion-like molecules	1	25.9×	0.219	PTPRF
Chaperone Mediated Autophagy	1	23.6×	0.219	IFT88
SHC1 events in ERBB2 signaling	1	22.7×	0.219	PRKCE
Effects of PIP2 hydrolysis	1	21.8×	0.219	PRKCE
Role of phospholipids in phagocytosis	1	21.8×	0.219	PRKCE
Semaphorin interactions	1	18.8×	0.219	SEMA6D
Insulin receptor recycling	1	18.1×	0.219	PTPRF
PI Metabolism	1	17.0×	0.219	RUFY1
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	1	17.0×	0.219	STIM1
Signaling by ERBB2	1	16.5×	0.219	PRKCE
Signaling by the B Cell Receptor (BCR)	1	16.5×	0.219	STIM1
Late endosomal microautophagy	1	15.5×	0.219	IFT88
DAG and IP3 signaling	1	15.1×	0.219	PRKCE
GABA receptor activation	1	15.1×	0.219	GABRR1
GPCR downstream signalling	3	6.2×	0.219	ADM, ANXA1, PRKCE
GPCR ligand binding	2	6.1×	0.219	ADM, ANXA1
Signaling by GPCR	3	5.7×	0.219	ADM, ANXA1, PRKCE
G alpha (q) signalling events	2	5.5×	0.219	ANXA1, PRKCE
Response of endothelial cells to shear stress	1	14.3×	0.223	ADM

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 34 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cell surface receptor protein tyrosine phosphatase signaling pathway	2	123.9×	0.028	PTPRF, PTPRU
positive regulation of vasculogenesis	2	76.2×	0.038	RIN2, ADM
toxin catabolic process	1	495.6×	0.038	PRKCE
regulation of interleukin-1 production	1	495.6×	0.038	ANXA1
D-amino acid metabolic process	1	495.6×	0.038	DAOA
negative regulation of receptor binding	1	495.6×	0.038	PTPRF
positive regulation of progesterone biosynthetic process	1	495.6×	0.038	ADM
positive regulation of synaptic transmission, GABAergic	2	58.3×	0.038	NALCN, PRKCE
cell-substrate adhesion	2	45.1×	0.038	SORBS1, PRKCE
stress fiber assembly	2	45.1×	0.038	SORBS1, PDLIM1
transmission of nerve impulse	2	38.1×	0.038	CNTNAP2, CACNG5
positive regulation of wound healing	2	31.0×	0.038	ANXA1, PRKCE
protein localization to cell surface	2	29.2×	0.038	ASTN2, PTPRU
synaptic transmission, GABAergic	2	29.2×	0.038	GABRR1, PRKCE
limbic system development	1	247.8×	0.055	CNTNAP2
negative regulation of rDNA heterochromatin formation	1	247.8×	0.055	PHF8
superior temporal gyrus development	1	247.8×	0.055	CNTNAP2
regulation of leukocyte migration	1	165.2×	0.055	ANXA1
TRAM-dependent toll-like receptor 4 signaling pathway	1	165.2×	0.055	PRKCE
regulation of calcium-dependent activation of synaptic vesicle fusion	1	165.2×	0.055	ERC2
deactivation of mitotic spindle assembly checkpoint	1	165.2×	0.055	MAD1L1
negative regulation of DNA damage checkpoint	1	165.2×	0.055	BRD4
myoblast migration involved in skeletal muscle regeneration	1	123.9×	0.055	ANXA1
establishment or maintenance of actin cytoskeleton polarity	1	123.9×	0.055	PDLIM1
neuron projection regeneration	1	123.9×	0.055	PTPRF
response to silicon dioxide	1	123.9×	0.055	IFT88
clustering of voltage-gated potassium channels	1	123.9×	0.055	CNTNAP2
regulation of hormone secretion	1	123.9×	0.055	ANXA1
maintenance of presynaptic active zone structure	1	123.9×	0.055	ERC2
protein localization to juxtaparanode region of axon	1	123.9×	0.055	CNTNAP2

Therapeutics

Drugs indicated or in trials for this disease

5 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Chlorpromazine	Approved (phase 4)
Flibanserin	Approved (phase 4)
Haloperidol	Approved (phase 4)
Olanzapine	Approved (phase 4)
Paliperidone	Approved (phase 4)

12 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Aripiprazole	Phase 3
Brexpiprazole	Phase 3
Mifepristone	Phase 3
Quetiapine	Phase 3
Risperidone	Phase 3
Rituximab	Phase 3
Acetylcysteine	Phase 2
Cannabidiol	Phase 2
Dexmedetomidine	Phase 2
Glycine	Phase 2
Serine	Phase 2
Taurine	Phase 2

Drug target analysis

Approved (phase 4): 5 · Phase ≥3: 5 · Phased (≥1): 7 · Undrugged: 33

Druggability breadth: 12 of 40 evidence-associated genes (30%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
STIM1	TERIFLUNOMIDE
BRD4	ACETAMINOPHEN
CACNG5	NIMODIPINE
GABRR1	LINDANE
PRKCE	INGENOL MEBUTATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRD4	31	4
PRKCE	21	4
GABRR1	5	4
STIM1	2	4
CACNG5	2	4
ANXA1	1	2
PTPRF	1	2
TRPS1	0	0
CNTNAP2	0	0
SORBS1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
TERIFLUNOMIDE	4	STIM1
ACETAMINOPHEN	4	BRD4
FEDRATINIB	4	BRD4, PRKCE
NITROXOLINE	4	BRD4
ROMIDEPSIN	4	BRD4
BELINOSTAT	4	BRD4
PANOBINOSTAT	4	BRD4
ALPRAZOLAM	4	BRD4
LENALIDOMIDE	4	BRD4
NORFLOXACIN	4	BRD4
VORINOSTAT	4	BRD4
NIMODIPINE	4	CACNG5
TACRINE	4	CACNG5
LINDANE	4	GABRR1
AMINOLEVULINIC ACID	4	GABRR1
INGENOL MEBUTATE	4	PRKCE
MIDOSTAURIN	4	PRKCE
TAMOXIFEN	4	PRKCE
RUXOLITINIB	4	PRKCE
BOSUTINIB	4	PRKCE
VOLASERTIB	3	BRD4
DINACICLIB	3	BRD4
TACEDINALINE	3	BRD4
APABETALONE	3	BRD4
PELABRESIB	3	BRD4
SURAMIN	3	PRKCE
FASUDIL	3	PRKCE
ALVOCIDIB	3	PRKCE
CURCUMIN	3	PRKCE
ENZASTAURIN HYDROCHLORIDE	3	PRKCE

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 6.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRD4	4,603	Binding:4569, Functional:30, ADMET:4
PRKCE	722	Binding:707, Functional:14, ADMET:1
PTPRF	136	Binding:135, Functional:1
GABRR1	55	Binding:29, Functional:26
STIM1	35	Binding:33, Functional:1, ADMET:1
PHF8	26	Binding:26
CACNG5	13	Binding:13
ANXA1	13	Binding:13
ADM	3	Binding:3
SORBS1	1	Binding:1
B3GALT5	1	Binding:1
PTPRU	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PHF8	1.14.11.65, 1.14.18.B1	[histone H3]-dimethyl-L-lysine9 demethylase,
POMGNT2	2.4.1.312	protein O-mannose beta-1,4-N-acetylglucosaminyltransferase
PRKCE	2.7.11.13	protein kinase C
PTPRF	3.1.3.48	protein-tyrosine-phosphatase
PTPRN2	3.1.3.48	protein-tyrosine-phosphatase
PTPRU	3.1.3.48	protein-tyrosine-phosphatase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
BRD4	4,603
PRKCE	722
PTPRF	136

Pharmacogenomics

Cohort genes with a PharmGKB record: 40; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
TERIFLUNOMIDE	4	STIM1
ACETAMINOPHEN	4	BRD4
FEDRATINIB	4	BRD4, PRKCE
NITROXOLINE	4	BRD4
ROMIDEPSIN	4	BRD4
BELINOSTAT	4	BRD4
PANOBINOSTAT	4	BRD4
ALPRAZOLAM	4	BRD4
LENALIDOMIDE	4	BRD4
NORFLOXACIN	4	BRD4
VORINOSTAT	4	BRD4
NIMODIPINE	4	CACNG5
TACRINE	4	CACNG5
LINDANE	4	GABRR1
AMINOLEVULINIC ACID	4	GABRR1
INGENOL MEBUTATE	4	PRKCE
MIDOSTAURIN	4	PRKCE
TAMOXIFEN	4	PRKCE
RUXOLITINIB	4	PRKCE
BOSUTINIB	4	PRKCE
VOLASERTIB	3	BRD4
DINACICLIB	3	BRD4
TACEDINALINE	3	BRD4
APABETALONE	3	BRD4
PELABRESIB	3	BRD4
SURAMIN	3	PRKCE
FASUDIL	3	PRKCE
ALVOCIDIB	3	PRKCE
CURCUMIN	3	PRKCE
ENZASTAURIN HYDROCHLORIDE	3	PRKCE

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	5	STIM1, BRD4, CACNG5, GABRR1, PRKCE
B	Phased (≥1) drug, not yet approved	2	ANXA1, PTPRF
C	Druggable family + PDB, no drug	6	ASTN2, NALCN, CNTN5, POMGNT2, PTPRN2, PTPRU
D	Druggable family + AlphaFold only, no drug	2	DIPK1A, IGSF5
E	Difficult family or no structure, no drug	25	TRPS1, CNTNAP2, SORBS1, SHC4, SEMA6D, MYO18B, RIN2, NPAS3, RUFY1, CCNL1 (+15 more)

Undrugged target profiles

33 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TRPS1	0	—
CNTNAP2	0	—
SORBS1	1	—
SHC4	0	—
SEMA6D	0	—
ASTN2	0	—
MYO18B	0	—
RIN2	0	—
NALCN	0	—
NPAS3	0	—
RUFY1	0	—
CCNL1	0	—
IFT88	0	—
PDLIM1	0	—
PHF8	26	—
DAOA	0	—
CNTN5	0	—
CYCSP44	0	—
ADM	3	—
POMGNT2	0	—
LRRIQ3	0	—
FAM110B	0	—
DLGAP1	0	—
NCKAP5	0	—
ERC2	0	—
DIPK1A	0	—
LEKR1	0	—
TMEM212	0	—
IGSF5	0	—
MAD1L1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 493.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	416
PHASE3	24
PHASE2	20
PHASE1	14
PHASE4	10
PHASE2/PHASE3	5
EARLY_PHASE1	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04289142	PHASE4	RECRUITING	Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT00001658	PHASE4	COMPLETED	Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00259883	PHASE4	COMPLETED	Combination Of PAXIL Tablet And Benzodiazepines
NCT00288782	PHASE4	COMPLETED	PET Neuroimaging of [11C]Mirtazapine
NCT01783912	PHASE4	COMPLETED	Helping Those With Mental Illness Quit Smoking
NCT02022709	PHASE4	COMPLETED	Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
NCT03655847	PHASE4	UNKNOWN	Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection
NCT03830398	PHASE4	UNKNOWN	Comparison of Drugs on Headache Treatment After ECT Treatment
NCT04781998	PHASE4	COMPLETED	Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?
NCT05508789	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5)
NCT05738486	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6)
NCT05946486	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.
NCT06387290	PHASE3	RECRUITING	Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
NCT07497711	PHASE2/PHASE3	RECRUITING	Virtual Menstrual Pain Approaches in Females
NCT00034762	PHASE3	COMPLETED	Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer’s Disease
NCT00034892	PHASE3	COMPLETED	CAFE Comparison of Atypicals in First Episode of Psychosis
NCT00035802	PHASE3	COMPLETED	A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
NCT00183313	PHASE3	COMPLETED	Improving Primary Care in Patients With Mental Disorders
NCT00183716	PHASE3	COMPLETED	The Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women
NCT00216502	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer’s Disease
NCT00240695	PHASE3	COMPLETED	A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
NCT00260013	PHASE2/PHASE3	COMPLETED	Transition Into Primary-care Psychiatry (TIPP)
NCT00561574	PHASE3	COMPLETED	A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
NCT00561821	PHASE3	COMPLETED	Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
NCT00631657	PHASE3	COMPLETED	A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
NCT00692081	PHASE2/PHASE3	COMPLETED	Social Competence Training for Adolescents With Borderline Intellectual Functioning
NCT00750919	PHASE3	TERMINATED	Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
NCT00942097	PHASE2/PHASE3	COMPLETED	Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder
NCT01201187	PHASE3	COMPLETED	Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD
NCT01360632	PHASE3	COMPLETED	Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
NCT01360645	PHASE3	COMPLETED	Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
NCT01360866	PHASE3	COMPLETED	Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
NCT01407120	PHASE2/PHASE3	COMPLETED	15 Year Follow-up of New Beginnings Program for Divorced Families
NCT01536210	PHASE3	COMPLETED	Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)
NCT01727726	PHASE3	COMPLETED	A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
NCT01862640	PHASE3	COMPLETED	A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer’s Agitation
NCT01922258	PHASE3	COMPLETED	Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type
NCT02196506	PHASE3	COMPLETED	Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
NCT05554094	PHASE2	ACTIVE_NOT_RECRUITING	Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BREXPIPRAZOLE	4	7
FLUOXETINE	4	6
PAROXETINE	4	4
PRUCALOPRIDE	4	4
CITALOPRAM	4	3
FLUVOXAMINE	4	3
DONANEMAB	4	2
GALANTAMINE HYDROBROMIDE	4	2
GANAXOLONE	4	2
AMOXICILLIN	4	1
FLORBETABEN F18	4	1
LAMOTRIGINE	4	1
MIDAZOLAM	4	1
MIRTAZAPINE	4	1
NICOTINE	4	1
OLIVE OIL	4	1
PALIPERIDONE PALMITATE	4	1
QUETIAPINE FUMARATE	4	1
ROTIGOTINE	4	1
SERTRALINE	4	1
TOPIRAMATE	4	1
TROMETHAMINE	4	1
ZOPICLONE	4	1
ESMIRTAZAPINE	3	5
LEUCINE	3	1
OMEGA-3 FATTY ACIDS	3	1
PSILOCYBIN	3	1
PEGIPANERMIN	2	3
IOMAZENIL	2	1
MEBUFOTENIN	2	1